CACS Drug Market Accelerates at 3.9% CAGR to 2033, Reaching USD 3.0 Billion; Strongest Growth in North America (43%); Key Companies: Pfizer, Incyte, PsiOxus Therapeutics & Aphios

The global Cancer Anorexia-Cachexia Syndrome (CACS) Drug Market was valued at USD 2.2 billion in 2024 and is projected to reach USD 3.0 billion by 2033, registering a CAGR of 3.9 percent during 2025-2033. The market includes appetite stimulants, metabolic modulators, anti-inflammatory agents and supportive-care drugs used to manage severe weight loss and muscle wasting in cancer patients. Rising global cancer prevalence, increasing number of late-stage diagnoses and growing clinical recognition of cachexia as a treatable condition are key factors driving market demand.

Market expansion is further supported by ongoing development of novel therapies, combination treatment approaches and increasing emphasis on improving nutritional status and quality of life in oncology care. North America currently holds the largest market share due to advanced cancer care infrastructure and higher treatment adoption, while Asia Pacific is expected to grow rapidly driven by rising cancer incidence and improving healthcare access in emerging economies.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/cancer-anorexia-cachexia-syndrome-drug-market?sai-v

The Cancer Anorexia-Cachexia Syndrome (CACS) Drug Market is advancing supportive oncology care with emerging therapies designed to improve appetite, preserve muscle mass, and enhance quality of life for cancer patients..

Key Developments

United States

✅ October 2025: U.S. biotech companies advanced development of multi-target CACS therapies combining appetite stimulants, anti-inflammatory agents, and muscle-preserving compounds to reduce cancer-induced weight loss.

✅ August 2025: American cancer centers expanded clinical trials for ghrelin receptor agonists and novel anabolic agents aimed at improving lean body mass and patient survival outcomes.

✅ May 2025: U.S. pharmaceutical researchers introduced AI-assisted modeling platforms to accelerate discovery of metabolic modulators designed to counter severe cancer-related muscle wasting.

Japan

✅ September 2025: Japanese oncology researchers developed next-generation CACS drug candidates targeting cytokine-driven inflammation pathways associated with rapid muscle degradation.

✅ June 2025: Japan's hospitals increased adoption of combination nutritional-pharmacological CACS management protocols integrating omega-3 formulations with anti-cachexia drugs.

✅ March 2025: Japanese pharmaceutical companies progressed early-stage studies on selective androgen receptor modulators (SARMs) designed to restore functional strength in late-stage cancer patients.

Mergers & Acquisitions

United States

✅ July 2025: A U.S.-based oncology drug manufacturer acquired a metabolic-therapy startup developing peptide-based appetite stimulants for advanced cancer cachexia patients.

Japan

✅ February 2025: A Japanese pharmaceutical firm partnered with a domestic biotech company to co-develop anti-inflammatory CACS therapies targeting IL-6 and TNF-α pathways.

✅ January 2025: A Japan-based oncology solutions provider formed a strategic collaboration with a U.S. research institute to accelerate global development of novel CACS drug combinations.

Key Players
Pfizer Inc | Helsinn Healthcare | Acacia Pharma Ltd | PsiOxus Therapeutics Ltd | Incyte Corp | Aeterna Zentaris Inc | Obexia AG | Aphios Corporation | Merck & Co | Novartis AG

Key Highlights
• Pfizer Inc - Holds 14.8% share of the global oncology supportive care and cancer therapeutics market, driven by its strong pipeline, targeted therapies, and extensive oncology portfolio.

• Helsinn Healthcare - Accounts for 9.6% market share, supported by its leadership in cancer supportive care products, especially antiemetic therapies (e.g., AKYNZEO, ALOXI).

• Acacia Pharma Ltd - Maintains 4.1% share, known for its postoperative and cancer-related nausea management products and expanding partnerships in oncology care.

• PsiOxus Therapeutics Ltd - Holds 3.4% share, driven by its innovative oncolytic immunotherapy pipeline focused on tumor-selective viral delivery platforms.

• Incyte Corp - Represents 10.7% share, backed by its strong oncology and hematology products such as Jakafi, and continued investment in immuno-oncology research.

• Aeterna Zentaris Inc - Accounts for 2.8% share, supported by its targeted endocrine-related oncology therapies and orphan cancer treatment developments.

• Obexia AG - Maintains 2.1% share, focused on next-generation cancer immunotherapies and metabolic pathway-targeting cancer treatments.

• Aphios Corporation - Holds 3.9% share, recognized for its nanoparticle-based drug delivery platforms and cancer supportive therapy innovations.

• Merck & Co - Represents 17.2% share, driven by its blockbuster oncology drug Keytruda and broad portfolio in immuno-oncology and targeted therapies.

• Novartis AG - Accounts for 13.4% share, with strong global presence in targeted cancer therapies, cell therapies, radioligand treatments, and supportive care drugs.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=cancer-anorexia-cachexia-syndrome-drug-market?sai-v

Market Drivers

• Rising prevalence of cancer worldwide, increasing the incidence of cancer-associated anorexia and cachexia conditions.

• Growing need for effective therapies that support weight gain, muscle mass retention, and improved quality of life in advanced cancer patients.

• Increasing adoption of multimodal treatment approaches combining pharmacological, nutritional, and metabolic therapies.

• Rising demand for appetite-stimulating and anti-inflammatory drugs to manage severe cancer-related weight loss.

• Advancements in drug development targeting metabolic pathways, cytokine modulation, and muscle protein synthesis.

• Growing awareness among oncologists regarding early identification and management of CACS.

• Expanding clinical research focused on novel drug combinations, including ghrelin agonists, anti-myostatic agents, and progestogens.

Industry Developments

• Development of ghrelin mimetic drugs and selective androgen receptor modulators (SARMs) to improve lean body mass in CACS patients.

• Clinical trials evaluating the efficacy of anti-inflammatory agents, cytokine inhibitors, and metabolic modulators for cachexia management.

• Launch of advanced appetite stimulants with improved safety profiles for cancer-associated anorexia.

• Growing pipeline of investigational drugs targeting muscle wasting through myostatin inhibition.

• Collaboration between pharma companies and oncology centers to develop combination therapies for better symptom control.

• Increasing adoption of digital tools for nutritional monitoring and personalized CACS treatment programs.

• Expansion of guidelines for early nutritional intervention to complement pharmacological therapies.

Regional Insights
• North America - 43% driven by "high cancer incidence, strong clinical research ecosystem, and growing adoption of advanced CACS therapies."

• Europe - 31% supported by "well-established oncology care systems, growing use of appetite stimulants, and rising focus on palliative cancer care."

• Asia Pacific - 20% fueled by "increasing cancer burden, improving access to oncology treatments, and rising awareness of cachexia management."

• Latin America - 4% driven by "expanding cancer treatment infrastructure and growing demand for supportive care therapies."

• Middle East & Africa - 2% supported by "improving oncology services and rising adoption of symptomatic management therapies for cancer patients."

Key Segments:

➥ By Product Type
Progestogens are widely used for managing menstrual disorders, endometriosis, hormonal imbalance, and reproductive health conditions due to their regulatory role in the menstrual cycle.
Corticosteroids are prescribed for their anti-inflammatory and immunosuppressive properties, supporting treatment of severe gynecological inflammation and hormonal-related disorders.
Combination therapies integrate multiple therapeutic agents to improve treatment outcomes, enhance hormonal balance, or manage complex reproductive and endocrine health conditions.
Others include emerging hormonal drugs and supportive medications used in specialized gynecological or endocrine treatments.

➥ By Distribution Channel
Hospital pharmacies account for a major share due to the high volume of prescriptions for hormonal therapies and inpatient treatments.
Retail pharmacies offer broad accessibility for chronic therapy prescriptions and routine hormonal treatments.
Online pharmacies are expanding rapidly, driven by convenience, home delivery, and increasing consumer acceptance of digital healthcare platforms.
Others include specialty pharmacies and healthcare distributors offering targeted hormonal and endocrine therapy solutions.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/cancer-anorexia-cachexia-syndrome-drug-market?sai-v
Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.